ImmunityBio (IBRX) SEC Filings: History & Chart

ImmunityBio, Inc.(IBRX)

Biotechnology · San Diego, CA

$9.69-0.69 (-6.65%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About ImmunityBio, Inc.

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

San Diego, CA

688 employees

immunitybio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Richard Gerald Adcock

View full financials

Form	Filing Date	Accepted	Document
SC 13D/A	Aug 6, 2026	Aug 6, 2026	View filing
10-Q	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jul 1, 2026	Jul 1, 2026	View filing
4	Jun 26, 2026	Jun 26, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 10, 2026	Jun 10, 2026	View filing
8-K	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
8-K	May 18, 2026	May 18, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
DEFA14A	Apr 30, 2026	Apr 29, 2026	View filing
DEF 14A	Apr 30, 2026	Apr 29, 2026	View filing
ARS	Apr 30, 2026	Apr 29, 2026	View filing
8-K	Apr 9, 2026	Apr 9, 2026	View filing
8-K	Apr 6, 2026	Apr 6, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
8-K	Mar 31, 2026	Mar 31, 2026	View filing
4	Feb 26, 2026	Feb 26, 2026	View filing
SC 13D/A	Feb 25, 2026	Feb 25, 2026	View filing
4	Feb 24, 2026	Feb 24, 2026	View filing
4	Feb 24, 2026	Feb 24, 2026	View filing

SEC Filings

Recent Filings